Case Law Takeda Canada Inc. v. Apotex Inc.,

Takeda Canada Inc. v. Apotex Inc.,

Document Cited Authorities (70) Cited in (5) Related (3)
2 cases
Document | Federal Court (Canada) – 2024
Boehringer Ingelheim (Canada) Ltd. v. Jamp Pharma Corporation,
"...Construction A. Legal Principles [58] I recently summarized the principles of claims construction in Takeda Canada Inc v Apotex Inc, 2024 FC 106 at paragraphs 69-74 [Takeda]. These principles, which are equally applicable here, are repeated as follows. [59] The first task for the Court in a..."
Document | Federal Court (Canada) – 2025
Alexion Pharma v. Amgen Canada,
"...the invention. [45] It is the person, or team of individuals, that would work the patent in a real sense: Takeda Canada Inc v Apotex Inc, 2024 FC 106 [Takeda] at para 76; Alcon Canada Inc v Cobalt Pharmaceuticals Company, 2014 FC 462 at para 37, aff’d 2015 FCA 191, 2015 FCA [46] Where the P..."

Try vLex and Vincent AI for free

Start a free trial
3 firm's commentaries
Document | Mondaq Canada – 2024
DEXILANT Formulation Patent Invalid And Not Infringed By Apotex
"...and failure to disclose the factual basis and line of reasoning for sound prediction of utility: Takeda Canada Inc v Apotex Inc, 2024 FC 106. Background DEXILANT is a "pulsatile release formulation ... that includes two types of delayed-release beads containing dexlansoprazole", and release..."
Document | Mondaq Canada – 2024
Dexlansoprazole Formulation Patent Invalid And Not Infringed By Apotex
"...and failure to disclose the factual basis and line of reasoning for sound prediction of utility: Takeda Canada Inc v Apotex Inc, 2024 FC 106. Background DEXILANT is a "pulsatile release formulation ... that includes two types of delayed-release beads containing dexlansoprazole", and release..."
Document | Mondaq Canada – 2025
Avoiding The Hindsight Trap In The Context Of A Patent Obviousness Analysis
"...J.) 4. Molo Design Ltd v Chanel Canada ULC, 2024 FC 1260 at para 300 (McHaffie J.) 5. See most recently Takeda Canada Inc v Apotex Inc, 2024 FC 106 at para 198 (Furlanetto 6. Astrazeneca Canada Inc v Apotex Inc, 2015 FC 322 at para 231 (Barnes J.) see also Swist v Meg Energy Corp, 2021 FC 1..."

Try vLex and Vincent AI for free

Start a free trial

Experience vLex's unparalleled legal AI

Access millions of documents and let Vincent AI power your research, drafting, and document analysis — all in one platform.

Start a free trial

Start Your 3-day Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant

  • Access comprehensive legal content with no limitations across vLex's unparalleled global legal database

  • Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength

  • Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities

  • Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting

vLex

Start Your 3-day Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant

  • Access comprehensive legal content with no limitations across vLex's unparalleled global legal database

  • Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength

  • Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities

  • Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting

vLex
2 cases
Document | Federal Court (Canada) – 2024
Boehringer Ingelheim (Canada) Ltd. v. Jamp Pharma Corporation,
"...Construction A. Legal Principles [58] I recently summarized the principles of claims construction in Takeda Canada Inc v Apotex Inc, 2024 FC 106 at paragraphs 69-74 [Takeda]. These principles, which are equally applicable here, are repeated as follows. [59] The first task for the Court in a..."
Document | Federal Court (Canada) – 2025
Alexion Pharma v. Amgen Canada,
"...the invention. [45] It is the person, or team of individuals, that would work the patent in a real sense: Takeda Canada Inc v Apotex Inc, 2024 FC 106 [Takeda] at para 76; Alcon Canada Inc v Cobalt Pharmaceuticals Company, 2014 FC 462 at para 37, aff’d 2015 FCA 191, 2015 FCA [46] Where the P..."

Try vLex and Vincent AI for free

Start a free trial

Start Your 3-day Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant

  • Access comprehensive legal content with no limitations across vLex's unparalleled global legal database

  • Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength

  • Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities

  • Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting

vLex

Start Your 3-day Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant

  • Access comprehensive legal content with no limitations across vLex's unparalleled global legal database

  • Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength

  • Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities

  • Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting

vLex
3 firm's commentaries
Document | Mondaq Canada – 2024
DEXILANT Formulation Patent Invalid And Not Infringed By Apotex
"...and failure to disclose the factual basis and line of reasoning for sound prediction of utility: Takeda Canada Inc v Apotex Inc, 2024 FC 106. Background DEXILANT is a "pulsatile release formulation ... that includes two types of delayed-release beads containing dexlansoprazole", and release..."
Document | Mondaq Canada – 2024
Dexlansoprazole Formulation Patent Invalid And Not Infringed By Apotex
"...and failure to disclose the factual basis and line of reasoning for sound prediction of utility: Takeda Canada Inc v Apotex Inc, 2024 FC 106. Background DEXILANT is a "pulsatile release formulation ... that includes two types of delayed-release beads containing dexlansoprazole", and release..."
Document | Mondaq Canada – 2025
Avoiding The Hindsight Trap In The Context Of A Patent Obviousness Analysis
"...J.) 4. Molo Design Ltd v Chanel Canada ULC, 2024 FC 1260 at para 300 (McHaffie J.) 5. See most recently Takeda Canada Inc v Apotex Inc, 2024 FC 106 at para 198 (Furlanetto 6. Astrazeneca Canada Inc v Apotex Inc, 2015 FC 322 at para 231 (Barnes J.) see also Swist v Meg Energy Corp, 2021 FC 1..."

Try vLex and Vincent AI for free

Start a free trial